Core Viewpoint - The company, Haizheng Pharmaceutical, has received approval from the U.S. FDA for its clinical trial application for the drug HS387, which is a selective KIF18A inhibitor aimed at treating advanced solid tumors such as high-grade serous ovarian cancer and non-small cell lung cancer [1] Group 1 - The company announced the approval of its clinical trial application for HS387 by the U.S. FDA [1] - HS387 is developed in-house and targets advanced solid tumors [1] - The drug is specifically intended for high-grade serous ovarian cancer and non-small cell lung cancer [1]

海正药业公告称，公司申报的HS387片药品临床试验申请获美国FDA批准，可在美国开展临床试验。该 药是公司自主研发的选择性KIF18A抑制剂，拟用于治疗晚期实体瘤，此前已获国家药监局临床试验批 准。目前，国内外有多款KIF18A抑制剂进入临床研发阶段，尚无药物上市。不过，药物获批上市还需 开展一系列临床试验，短期内对公司经营业务影响不大，提醒投资者注意风险。 ...

Core Viewpoint - The report highlights the trends and statistics in the Chinese chemical pharmaceutical industry, indicating a slight decline in production while maintaining overall growth in the sector [1]. Industry Summary - As of October 2025, the production of chemical pharmaceutical raw materials in China reached 313,000 tons, showing a year-on-year decrease of 1.6% [1]. - From January to October 2025, the cumulative production of chemical pharmaceutical raw materials was 3,049,000 tons, reflecting a cumulative growth of 1.3% [1]. - The report is based on data from the National Bureau of Statistics and is compiled by Zhiyan Consulting, a leading industry consulting firm in China [1]. Company Summary - Listed companies in the sector include Heng Rui Medicine, East China Pharmaceutical, Lizhu Group, Baiyunshan, North China Pharmaceutical, Haizheng Pharmaceutical, Fosun Pharmaceutical, Kelun Pharmaceutical, Enhua Pharmaceutical, and Xianju Pharmaceutical [1].

Core Viewpoint - The innovation in the pharmaceutical industry is a long and challenging process that brings significant returns for patients and societal development, with Zhejiang province focusing on regulatory reforms to enhance high-quality development in the sector [1]. Policy Empowerment: Releasing Financial Benefits - Regulatory reforms in Zhejiang aim to reduce institutional transaction costs for enterprises, thereby alleviating development burdens and broadening growth prospects [3]. - From January to September 2025, the biopharmaceutical and medical device industry cluster in Zhejiang achieved a revenue of 236.43 billion yuan and a total profit of 30.52 billion yuan, with a profit growth of 4.4% year-on-year, ranking second in profit margin among 12 industry clusters in the province [3]. - The implementation of significant policies, such as the "14th Five-Year Plan" and the "35 Drug Policies," has created a comprehensive policy ecosystem for innovation [3]. Continuous Release of Benefits in Reform Areas - Reforms have led to a 77% acceleration in the review time for supplementary applications, a nearly 30% reduction in provincial enterprise inspections, and over 90% paperless administrative approval rates [4]. - Various pilot reforms, including optimized review and approval processes for drug applications and production licenses, have accelerated innovation in Zhejiang's pharmaceutical companies [4]. Service Support: Streamlining Result Transformation - The Zhejiang Provincial Drug Administration provides comprehensive support to companies in the innovation process, facilitating communication and problem-solving [7]. - During the "14th Five-Year Plan" period, Zhejiang approved 22 innovative drugs and achieved breakthroughs in traditional Chinese medicine [7]. Technical Support: Establishing a Comprehensive Network - Zhejiang has established six municipal and county-level pharmaceutical innovation and review service institutions, along with 32 flexible review service stations, creating a technical support network across the province [9]. - The Zhejiang Provincial Food and Drug Inspection Research Institute has set up drug registration inspection laboratories, speeding up registration inspection timelines by 50% [9]. Localized Support for Enterprises - Local service centers are effectively addressing the needs of enterprises by integrating resources for registration consultation and review guidance, significantly increasing the number of drug registration checks since 2025 [10]. - The Zhejiang Drug Administration is committed to continuous regulatory reforms to ensure the pharmaceutical industry becomes a key driver of high-quality development in the province [10].

Core Viewpoint - The company, Haizheng Pharmaceutical, highlights the potential of its product Favipiravir tablets (Hai Fukan) as a broad-spectrum antiviral agent with low resistance, indicating its applicability against various RNA viruses [1] Group 1: Product Information - Favipiravir tablets are characterized as an RNA polymerase inhibitor, showcasing broad-spectrum antiviral properties and low resistance [1] - The company is actively promoting the accessibility and awareness of the product by integrating internal and external resources [1] Group 2: Sales and Distribution - Offline sales efforts, including hospital access, are being comprehensively promoted [1] - Patients can also purchase the product through e-commerce channels, enhancing its availability [1]

证券日报网讯12月19日，海正药业（600267）在互动平台回答投资者提问时表示，公司严格按照相关法 律法规要求做好信息披露工作，不存在应披露未披露事项。公司始终秉持尊重与坦诚的态度，重视与广 大投资者的沟通，过去几年公司每年均与百余家机构投资者交流，今年以来已累计接待或反路演包括博 时、交银、汇添富、睿远、人保、广发等150余家调研交流。公司相信只要把基本面做好，通过战略布 局提速和市值管理配合，海正药业终会回归应有的市场价值。二级市场买卖交易系市场行为，请注意投 资风险，谨慎投资。 ...

证券日报网讯12月19日，海正药业（600267）在互动平台回答投资者提问时表示，公司发布回购股份方 案是基于对公司未来持续稳定发展的信心和对公司价值的高度认可，后续将根据回购方案及市场情况在 回购期限内择机实施回购，并及时履行信息披露义务。 ...

Group 1 - The company has received approval for a new veterinary drug, Methylprednisolone Tablets (for dogs), classified as a Category V new veterinary drug by the Ministry of Agriculture and Rural Affairs of the People's Republic of China [1] - The new drug is developed by Zhejiang Haizheng Animal Health Products Co., Ltd. in collaboration with seven other companies, and is intended for the treatment of inflammatory and allergic diseases in dogs [1] - The drug is indicated for conditions such as allergic or non-specific dermatitis, musculoskeletal diseases, and inflammation of the eyes/ears, among other steroid-responsive inflammatory/allergic diseases [1] Group 2 - The registration application for the new veterinary drug was submitted in October 2024, and the product is now ready for production and market launch pending the approval of the veterinary product number [1] - Currently, the company has not been able to obtain specific sales revenue data for similar products from other companies through public channels [2]

本报讯(记者袁传玺)天眼查App显示，近日，浙江凌愈制药有限公司成立，注册资本1亿元，经营范围包 括药品生产、药品批发、技术进出口、货物进出口等。股东信息显示，该公司由浙江圣兆药物科技股份 有限公司、海正药业（600267）共同持股。 ...

Core Viewpoint - The company is actively expanding its presence in the East China commercial market through strategic acquisitions and internationalization efforts [2][3]. Group 1: Acquisition of Zhejiang Medical Industry - The company announced that its subsidiary, Guangzhou Pharmaceutical, plans to acquire 100% equity of Zhejiang Medical Industry from Haizheng Pharmaceutical for a total consideration of 501 million yuan [1]. - Zhejiang Medical Industry is ranked among the top six pharmaceutical distribution companies in Zhejiang Province, with projected revenues of 4.245 billion yuan for 2024 and 2.920 billion yuan for the first quarter of 2025 [2]. - This acquisition is expected to enhance Guangzhou Pharmaceutical's customer network in Zhejiang and surrounding areas, optimizing its industrial layout in East China and improving market coverage [2]. Group 2: Investment in Nanjing Pharmaceutical - The company announced an investment in Nanjing Pharmaceutical through its subsidiary, Guangyao Phase II Fund, to acquire a portion of its shares by September 2025 [2]. - This investment aims to strengthen business cooperation with Nanjing Pharmaceutical, enhancing collaboration in capital, distribution channels, and traditional Chinese medicine, thereby optimizing the industrial layout in East China [2]. Group 3: Internationalization of Health Sector - In 2025, the company plans to accelerate the internationalization of its health sector, launching four international flavors in a global event in Shanghai [3]. - The international flavors have been gradually launched in countries like Singapore and Malaysia since November, and a local production cooperation framework has been signed with partners in Malaysia [3]. - The company is transitioning from product export to industry chain export and brand export, indicating a significant upgrade in its international strategy [3]. Group 4: Profit Forecast and Valuation - The company maintains its net profit forecasts for 2025 and 2026 at 3.12 billion yuan and 3.431 billion yuan, respectively [3]. - The current A-share price corresponds to a price-to-earnings ratio of 13.4 and 12.2 for 2025 and 2026, while the H-share price corresponds to 8.8 and 7.9 [3]. - The company maintains a target price of 34.0 yuan for A-shares and 23.0 HKD for H-shares, indicating potential upside of 32.5% and 24.7%, respectively [3].